Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Natural history, survival, and mortality
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Natural history, survival, and mortality

1 evidence topic · 1 source

Spontaneous improvement

“Spontaneous improvement may occur in 8–25% of cases” (opens the source at this quote in a new tab)